Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome
Status:
Completed
Trial end date:
2020-04-29
Target enrollment:
Participant gender:
Summary
The purpose of this prospective, international phase III/IV study is to assess the efficacy
and safety of metyrapone in patients with endogenous Cushing's syndrome during up to 36 weeks
of treatment. The ability of metyrapone (250 mg capsules) to normalize urinary free cortisol
(UFC) levels will be assessed during up to 36 weeks (9 months) of treatment.